the role of CAS in asymptomatic patients. The results of
ACAS5 and ACST6 favored CEA in the management of
these patients. ACAS demonstrated the superiority of CEA
over antiplatelet therapy alone for asymptomatic patients
with carotid stenosis of ⱖ60%. This trial recommended
CEA for these patients (aged ⬍80 years) as long as the
expected combined stroke and mortality rate for the individual surgeon was not